BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 9.1% – Still a Buy?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price rose 9.1% during trading on Wednesday . The stock traded as high as $8.80 and last traded at $8.83. Approximately 465,502 shares changed hands during mid-day trading, a decline of 80% from the average daily volume of 2,361,642 shares. The stock had previously closed at $8.09.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Barclays raised their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Evercore ISI boosted their price objective on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC boosted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $15.50.

BioCryst Pharmaceuticals Price Performance

The company has a 50 day moving average price of $7.65 and a 200 day moving average price of $7.70. The firm has a market cap of $1.78 billion, a PE ratio of -14.17 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The company had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. During the same quarter last year, the company earned ($0.19) EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 35.1% compared to the same quarter last year. On average, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BCRX. The Manufacturers Life Insurance Company raised its position in BioCryst Pharmaceuticals by 113.8% in the second quarter. The Manufacturers Life Insurance Company now owns 212,581 shares of the biotechnology company’s stock worth $1,314,000 after acquiring an additional 113,152 shares in the last quarter. Creative Planning raised its position in BioCryst Pharmaceuticals by 75.2% in the second quarter. Creative Planning now owns 46,613 shares of the biotechnology company’s stock worth $288,000 after acquiring an additional 20,014 shares in the last quarter. Sanctuary Advisors LLC purchased a new position in BioCryst Pharmaceuticals in the second quarter worth $164,000. SG Americas Securities LLC purchased a new position in BioCryst Pharmaceuticals in the third quarter worth $1,208,000. Finally, CWM LLC raised its position in BioCryst Pharmaceuticals by 201.7% in the third quarter. CWM LLC now owns 17,072 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 11,414 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.